About this condition
COMT Gene (Warrior / Worrier)
The COMT Val158Met polymorphism is a common functional variant in the catechol-O-methyltransferase gene that influences how your brain processes dopamine. The COMT enzyme degrades dopamine and other catecholamine neurotransmitters in the prefrontal cortex — the brain region controlling focus, decision-making, and emotional regulation. The Met/Met genotype ('Worrier') produces 3–4-fold lower enzyme activity, resulting in higher dopamine levels and better cognitive performance under normal conditions but greater anxiety under stress. The Val/Val genotype ('Warrior') produces higher enzyme activity, lower baseline dopamine, but superior emotional resilience and stress tolerance.
This polymorphism is not a disease-causing mutation — it is normal human variation affecting cognition, pain sensitivity, and stress response. The Met allele frequency is approximately 50% in European populations. The inverted-U model of dopamine function explains why neither extreme is inherently 'better': very high dopamine impairs focus and increases anxiety; very low dopamine impairs motivation and cognition. Your specific genotype influences your optimal cognitive and emotional operating point.
COMT function does not act in isolation — it interacts dynamically with other dopaminergic pathway genes (MAOA, DRD2, DAT1, DBH) and is modulated by stress, sleep, exercise, and diet. Understanding your COMT status provides self-knowledge about your stress response patterns, cognitive style, and medication sensitivities. It enables informed decisions about work environment, medication choices, and stress-management strategies tailored to your neurobiology.
COMT interacts with multiple dopaminergic pathway genes — a single-SNP test misses the broader neurochemical context that whole genome sequencing captures.
- Gene locus
- COMT (22q11.21) — Val158Met polymorphism (rs4680)
